161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Titel:
161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Auteur:
Tutt, A. Nowecki, Z. Szoszkiewicz, R. Im, S-A. Arkenau, H-T. Armstrong, A. Jacot, W. Kim, J.H. Webster, M. Balmana, J. Delaloge, S. Lukashchuk, N. Odegbami, R. Casson, E. Loembe, A.B. Drachsler, M.W. Dean, E.J. Punie, K.